504846866 03/30/2018

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4893603

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MITCHELL A. DELONG	02/25/2011
JILL M. STURDIVANT	02/28/2011
SUSAN M. ROYALTY	03/06/2011

RECEIVING PARTY DATA

Name:	AERIE PHARMACEUTICALS, INC.	
Street Address:	2030 MAIN STREET	
City:	IRVINE	
State/Country:	CALIFORNIA	
Postal Code:	92614	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15941783

CORRESPONDENCE DATA

Fax Number: (949)253-0902

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 949-253-0900

Email: courtney.lines@klgates.com

Correspondent Name: K&L GATES LLP
Address Line 1: 1 PARK PLAZA
Address Line 2: TWELFTH FLOOR

Address Line 4: IRVINE, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER:	1959002.00106	
NAME OF SUBMITTER:	COURTNEY LINES	
SIGNATURE:	/Courtney Lines/	
DATE SIGNED:	03/30/2018	

Total Attachments: 3

source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif

> PATENT REEL: 045400 FRAME: 0556

504846866

ASSIGNMENT

Pursuant to our obligation to AERIE PHARMACEUTICALS, INC. (hereinafter referred to as "Assignee"), a Delaware corporation having its principal place of business at:

7020 Kit Creek Road, Suite 270 P.O. Box 12320 Research Triangle Park, North Carolina 27709

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

Mitchell A. deLong 2224 Pathway Drive Chapel Hill, North Carolina 27516

Jill Marie Sturdivant 3930 Crawford Dairy Road Chapel Hill, North Carolina 27516

Susan M. Royalty 907 Northwoods Drive Cary, North Carolina 27513

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and Interest -

- (1) in and to inventions described in a patent application titled "DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE" for which we filed United States Patent Application No. 12/694,965 (Atty. File No. 017425-9042-US00) (hereinafter the "U.S. utility patent application") which application claims the benefit of United States Provisional Patent Application No. 61/174,672, filed May 1, 2009 (hereinafter the "U.S. provisional patent application") (Atty. File No. 017425-9040-US00);
- (2) in and to the U.S. utility patent application, and the U.S. provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, 35 U.S.C. §111(b) provisional, 35 U.S.C. §111(a), and reissue applications) based upon said invention, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;
- (3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and



(4) under the International Convention in respect to the U.S. utility patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on either or both of the U.S. utility patent application and the U.S. provisional patent application.

And we hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

And the Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

2/25/201/

Date

Mitchell A. deLong

Date

Date

Susan M. Royalty

Q:\CLIENT\017425\9042\B2176518.1

Mr 2/2 (4) under the International Convention in respect to the U.S. utility patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on either or both of the U.S. utility patent application and the U.S. provisional patent application.

And we hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

And the Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

Date	Mitchell A. deLong
Date	
Date	Jill Marie Sturdivant
3-6-11	Lus Il ha
Date	Susan M. Royalty

Q:\CLIENT\017425\9042\B2176518.1